🇺🇸 Unfractionated heparin in United States

219 US adverse-event reports

Marketing authorisations

FDA

  • Status: approved

FDA

  • Application: NDA018237
  • Marketing authorisation holder: SANOFI AVENTIS US
  • Local brand name: CALCIPARINE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Death — 34 reports (15.53%)
  2. Renal Failure Acute — 31 reports (14.16%)
  3. Haemorrhage — 30 reports (13.7%)
  4. Thrombocytopenia — 23 reports (10.5%)
  5. Myocardial Infarction — 22 reports (10.05%)
  6. Drug Ineffective — 21 reports (9.59%)
  7. Pulmonary Embolism — 17 reports (7.76%)
  8. Haemoglobin Decreased — 14 reports (6.39%)
  9. Maternal Exposure During Pregnancy — 14 reports (6.39%)
  10. Deep Vein Thrombosis — 13 reports (5.94%)

Source database →

Unfractionated heparin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Unfractionated heparin approved in United States?

Yes. FDA has authorised it; FDA has authorised it.

Who is the marketing authorisation holder for Unfractionated heparin in United States?

Chen Jing is the originator. The local marketing authorisation holder may differ — check the official source linked above.